ORIGINAL RESEARCH article
Front. Oncol.
Sec. Hematologic Malignancies
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1633644
Real-World Australian Experience With Tisagenlecleucel for Relapsed/Refractory Diffuse Large B-Cell Lymphoma -Importance of Pre-CAR-T Optimization
Provisionally accepted- 1Royal Prince Alfred Hospital, Sydney, Australia
- 2University of Sydney, Sydney, Australia
- 3Institute of Haematology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia
- 4Statistical Revelations, Ocean Grove, Victoria, Australia
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Introduction: Up to 50% of patients with diffuse large B-cell lymphoma (DLBCL) relapse or are refractory to first-line therapy. Tisagenlecleucel, a CD19-directed chimeric antigen receptor (CAR)-T cell therapy, is approved for patients with relapsed/refractory (r/r) DLBCL in the third-line setting. Patients with r/r DLBCL treated with tisagenlecleucel in the real world have shown similar outcomes to those in clinical trials.We report a single-center real-world analysis of patients with r/r DLBCL treated with tisagenlecleucel.Results: As of December 31, 2024, 63 patients with r/r DLBCL had received tisagenlecleucel (median follow-up 15 months). Cytokine release syndrome occurred in 89%; 95% were grade 1/2. Immune effector cell-associated neurotoxicity syndrome was reported in 17% (10/11 cases mild; 1 case grade ≥3). Overall response rate was 79%, with 60% complete response (CR). Median duration of response was 26.4 months. Median progression-free survival (PFS) was 14.6 months and overall survival (OS) was 15.4 months. Patients whose response at day 30 was CR had a 42% reduction in risk of progression compared with those who achieved partial response (PR). High lactate dehydrogenase (LDH) at infusion was associated with a higher risk of disease progression (hazard ratio [HR] 2.1) and death (HR 2.65) than normal LDH, with the risk for progression increased 3.3fold in a multivariate model. Almost one third of our patients who achieved CR had normalized their LDH at the time of infusion from a previously elevated level, of whom 87% (13/15) had received bridging therapy. Lack of response to bridging was associated with an almost 2-fold increased risk of progression compared with responsive patients (3.1 vs 19.5 months; HR 1.9; 95% CI: 0.9-3.9, P=0.08).We demonstrated in this analysis that the safety and efficacy of tisagenlecleucel in patients with r/r DLBCL in an Australian real-world setting were better than in the pivotal JULIET clinical trial and other registry studies. We also confirmed the importance of achieving early CR and normalizing LDH levels at CAR-T cell infusion to reduce the risk of disease progression. Our results suggest that bridging therapy played an important role in optimizing outcomes by managing pre-CAR-T disease control.
Keywords: Min. 5-Max. 8): r/r DLBCL, car-t, Real-world, tisagenlecleucel, Relapsed, Refractory
Received: 23 May 2025; Accepted: 21 Jul 2025.
Copyright: © 2025 Ho, Vanguru, Burge, Wayte, Brown, Bryant, Dunkley, McCulloch, Khoo, Favaloro, Jeffrey, Solterbeck, Larsen and Abadir. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Phoebe Joy Ho, Royal Prince Alfred Hospital, Sydney, Australia
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.